PB1942: PARTIAL RESPONSE WITH LYMPHOCYTOSIS (PR-L) IS NOT APPLICABLE FOR ACALABRUTINIB. AN ITALIAN MULTICENTER EXPERIENCE OF REAL LIFE.

PB1942: PARTIAL RESPONSE WITH LYMPHOCYTOSIS (PR-L) IS NOT APPLICABLE FOR ACALABRUTINIB. AN ITALIAN MULTICENTER EXPERIENCE OF REAL LIFE.

Bibliographic Details
Main Authors:	Idanna Innocenti, Antonio Mosca, Annamaria Tomasso, Andrea Galitzia, Lydia Scarfò, Eugenio Galli, Roberta Laureana, Giulia Benintende, Veronica Mattiello, Francesca Morelli, Sabrina Chiriu, Maria Ilaria Del Principe, Giulia Zamprogna, Massimo Gentile, Nicole Fabbri, Francesco Autore, Paolo Sportoletti, Alberto Fresa, Gioacchino Catania, Marta Coscia, Alessandra Tedeschi, Alessandro Sanna, Marzia Varettoni, Paolo Ghia, Roberta Murru, Luca Laurenti
Format:	Article
Language:	English
Published:	Wiley 2023-08-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000974584.83737.e4

Similar Items

Kinetics of lymphocytosis in naïve chronic lymphocytic leukemia patients treated with covalent Bruton's tyrosine kinase inhibitors: An Italian multicenter real‐life experience
by: Idanna Innocenti, et al.
Published: (2024-12-01)

Relapsed/refractory pure red cell aplasia in chronic lymphocytic leukemia successfully treated with acalabrutinib: a case report and review of the literature
by: Alberto Fresa, et al.
Published: (2024-11-01)

PB1933: TREATMENT SEQUENCING AND OUTCOME OF CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS TREATED AT FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS: A THIRTY-YEAR SINGLE-CENTER EXPERIENCE.
by: Alberto Fresa, et al.
Published: (2023-08-01)

Measurable residual disease in chronic lymphocytic leukemia
by: Giulia Benintende, et al.
Published: (2023-02-01)

VEGF and IL-6 correlation in POEMS: a potential upcoming marker of active disease and early autologous BMT response.
by: Luca Laurenti, et al.
Published: (2022-01-01)

Another piece of the puzzle: is there a “nodal” monoclonal B-cell lymphocytosis?
by: Paolo Ghia
Published: (2011-08-01)

Clinical and molecular features of familial chronic lymphocytic leukemia: a pilot monocentric study
by: Giulia Benintende, et al.
Published: (2022-12-01)

Coexisting conditions and concomitant medications do not affect venetoclax management and survival in chronic lymphocytic leukemia
by: Anna Maria Frustaci, et al.
Published: (2022-10-01)

PB1872: ANTIBODY RESPONSES AFTER COVID-19 VACCINATION IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKAEMIA, EITHER TREATED OR NAÏVE. A MONOCENTRIC EXPERIENCE.
by: I. Innocenti, et al.
Published: (2022-06-01)

Highly similar genomic landscapes in monoclonal B-cell lymphocytosis and ultra-stable chronic lymphocytic leukemia with low frequency of driver mutations
by: Andreas Agathangelidis, et al.
Published: (2018-05-01)

Infrequent “chronic lymphocytic leukemia-specific” immunoglobulin stereotypes in aged individuals with or without low-count monoclonal B-cell lymphocytosis
by: Andreas Agathangelidis, et al.
Published: (2020-06-01)

P1305: NEPA VERSUS ONDANSETRON FOR THE PREVENTION OF CINV IN PATIENTS WITH MULTIPLE MYELOMA OR LYMPHOMA UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION. A MONOCENTRIC REAL-LIFE EXPERIENCE.
by: Idanna Innocenti, et al.
Published: (2023-08-01)

Obinutuzumab plus chlorambucil versus ibrutinib in previously untreated chronic lymphocytic leukemia patients without TP53 disruptions: A real-life CLL campus study
by: Andrea Visentin, et al.
Published: (2022-11-01)

Atypical lymphocytosis in leptospirosis
by: Viroj Wiwanitkit
Published: (2012-04-01)

P642: A MATCHING-ADJUSTED INDIRECT COMPARISON OF THE EFFICACY AND SAFETY OF ACALABRUTINIB VERSUS ZANUBRUTINIB IN RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA
by: Alan Skarbnik, et al.
Published: (2023-08-01)

COVID-19 in patients with chronic lymphocytic leukemia treated with venetoclax: what is the role of anti-CD20 antibody?
by: Francesco Autore, et al.
Published: (2025-01-01)

High-throughput analysis of the T cell receptor gene repertoire in low-count monoclonal B cell lymphocytosis reveals a distinct profile from chronic lymphocytic leukemia
by: Andreas Agathangelidis, et al.
Published: (2020-01-01)

Risk of hepatitis B virus reactivation in chronic lymphocytic leukemia patients receiving ibrutinib with or without antiviral prophylaxis. A retrospective multicentric GIMEMA study
by: Idanna Innocenti, et al.
Published: (2022-02-01)

Transient Headache and CSF Lymphocytosis
by: J Gordon Millichap
Published: (1995-10-01)

An Unusual Case of Atypical Lymphocytosis
by: Suresh Venugopal, et al.
Published: (2008-11-01)

P643: CUMULATIVE REVIEW OF HEART FAILURE WITH ACALABRUTINIB IN THE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA USING DATA FROM CLINICAL TRIALS AND POST-MARKETING EXPERIENCE
by: Paolo Ghia, et al.
Published: (2023-08-01)

Acalabrutinib Versus Investigator’s Choice in Relapsed/Refractory Chronic Lymphocytic Leukemia: Final ASCEND Trial Results
by: Paolo Ghia, et al.
Published: (2022-12-01)

PB1948: ACALABRUTINIB IN THE TREATMENT OF RICHTER SYNDROME
by: Tatyana Byalik, et al.
Published: (2023-08-01)

PB1861: ACALABRUTINIB IN THE TREATMENT OF RICHTER SYNDROME
by: T. Byalik, et al.
Published: (2022-06-01)

The role of acalabrutinib in adults with chronic lymphocytic leukemia
by: Bita Fakhri, et al.
Published: (2021-02-01)

Cardiovascular adverse events in patients with chronic lymphocytic leukemia receiving acalabrutinib monotherapy: pooled analysis of 762 patients
by: Jennifer R. Brown, et al.
Published: (2021-09-01)

Assessment of Peripheral Blood Lymphocytosis in Adults: Determination of Thresholds for Differential Diagnosis between Clonal and Reactive Lymphocytosis
by: Aya Chakroun, et al.
Published: (2021-11-01)

Peripheral Lymphocytosis in Angioimmunoblastic T-cell Lymphoma
by: C. Selvapriya, et al.
Published: (2024-12-01)

B Cell Lymphocytosis in Juvenile Dermatomyositis
by: Christopher Costin, et al.
Published: (2023-08-01)

Differences and similarities in the effects of ibrutinib and acalabrutinib on platelet functions
by: Jennifer Series, et al.
Published: (2019-11-01)

FRAILTY ASSESSMENT AS PREDICTOR OF BLEEDING FOR PATIENTS TREATED WITH ACALABRUTINIB
by: TX Carneiro, et al.
Published: (2023-10-01)

Acalabrutinib in management of chronic lymphocytic leukemia: An Indian perspective
by: Nitin Sood, et al.
Published: (2021-08-01)

Rapid response of omalizumab-resistant chronic urticaria to acalabrutinib
by: Diamond R. Guy, BS, et al.
Published: (2024-05-01)

P1509: CHRONIC OBSTRUCTIVE PULMONARY DISEASE AND PREVIOUS INFECTIONS HAD IMPACT ON INFECTIOUS COMPLICATIONS IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA TREATED WITH VENETOCLAX: A MULTICENTRE SEIFEM STUDY
by: Francesco Autore, et al.
Published: (2023-08-01)

P593: MULTIDIMENSIONAL ANALYSIS OF THE B CELL RECEPTOR OFFERS INSIGHT INTO THE ONTOGENETIC RELATIONSHIP OF MONOCLONAL B-CELL LYMPHOCYTOSIS WITH CHRONIC LYMPHOCYTIC LEUKEMIA
by: A. Agathangelidis, et al.
Published: (2022-06-01)

Ibrutinib does not affect ristocetin-induced platelet aggregation evaluated by light transmission aggregometry in chronic lymphocytic leukemia patients
by: Maria Adele Alberelli, et al.
Published: (2018-03-01)

What Are the Attributes Prioritized in the Choice of Therapy in Chronic Lymphocytic Leukemia? A Patient-physician Cross-matching Analysis of a Discrete Choice Experiment
by: Luca Laurenti, et al.
Published: (2022-09-01)

Extreme lymphocytosis in a dog with T-zone lymphoma
by: Bruna Voltolin de Sena, et al.
Published: (2023-12-01)

Immunophenotypic characterization and clinical outcome in cats with lymphocytosis
by: Emily D. Rout, et al.
Published: (2020-01-01)

Monoclonal B-cell lymphocytosis with renal involvement
by: Yao-Ko Wen
Published: (2018-01-01)